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Abstract
Background: We evaluated the usefulness of follow-up BRAFV600E mutation analysis using ultrasonography-guided fine-
needle aspiration (US-FNA) in diagnosis of thyroid nodules showing negative BRAFV600E mutation on prior analysis.
Methodology/Principal Finding: A total of 49 patients (men: 6, women: 43, mean age: 50.4 years) with 49 thyroid nodules
were included. Patients had undergone initial and follow-up US-FNA and subsequent BRAFV600E mutation analysis from US-
FNA aspirates. All patients had negative results on initial BRAFV600E mutation analysis. Clinicopathologic findings, US
assessment, and BRAFV600E mutation results were analyzed according to the final pathology. Of the 49 nodules, 12 (24.5%)
were malignant and 37 (75.5%) were benign. Seven (58.3%) of the 12 malignant nodules were positive for BRAFV600E
mutation on follow-up, all showing suspicious US features. Initial US-FNA cytology of the 7 nodules were non-diagnostic
(n = 2), benign (n = 2), or atypia (n = 3), while follow-up were benign (n = 1), indeterminate (n = 1), suspicious for malignancy
(n = 4), and malignancy (n = 1).
Conclusions/Significance: Follow-up BRAFV600E mutation analysis may be helpful in the diagnosis of selected thyroid
nodules negative for BRAFV600E mutation on initial analysis, which are assessed as suspicious malignant on US, diagnosed as
non-diagnostic, benign or atypia on follow-up US-FNA.
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Introduction
Recent reports worldwide show rapid increase in the incidence
of papillary thyroid carcinoma (PTC), the most common form of
thyroid cancer [1–4]. Molecular genetics have evolved remarkably
in the recent decade, and at the present time BRAF mutation is
the most commonly known genetic alteration in PTC [5–6].
BRAFV600E mutations found in PTC are a thymine to adenine
transversion at nucleotide 1799 (T1799A), leading to a substitution
of valine to glutamic acid at residue 600 of the protein
(V600E)[5,7–8]. This point mutation leads stimulation of MAPK
pathway, which is results in oncogenic activation in the thyroid.
BRAFV600E mutation is common and highly specific for conven-
tional PTC, and can be used for diagnosis, optimal sugical
planning, and postoperative patient management [9].
Up to the present date, ultrasonography-guided fine-needle
aspiration (US-FNA) has showed excellent performances and
considered the standard diagnostic method in the diagnosis of
various thyroid nodules detected on ultrasonography (US) [10–
14]. Major limitations of US-FNA are the indeterminate cytology
results such as ‘inadequate or non-diagnostic’, ‘follicular cells with
atypia’, ‘follicular neoplasm’, or ‘suspicious for malignancy’, which
consist of 10–30% of all cytology results [15]. BRAFV600E
mutation analysis has proven to be both useful and accurate as
an adjunctive diagnostic tool to US-FNA in providing additional
information in the differential diagnosis of PTC showing non-
diagnostic or indeterminate cytology results [7,16–18], especially
in a BRAFV600E mutation prevalent area such as Korea. Mostly,
BRAFV600E mutation analysis accompanies the initial US-FNA of
a thyroid nodule based on clinical or radiological suspicion for
malignancy, and has been proven more effective when performed
at the time of initial cytologic analysis [17]. To our knowledge, no
other studies have reported results on the diagnostic significances
of performing consecutive follow-up BRAFV600E mutation analysis
on the differential diagnosis of thyroid nodules, especially in
nodules with negative results on prior BRAFV600E mutation
analysis which had ambiguous cytology such as non-diagnostic and
atypia, or discordant cytology to US features, and whether if this
additional analysis of BRAFV600E mutation is useful or not has not
been established. Therefore, we evaluated the usefulness of follow-
up BRAFV600E mutation analysis using US-FNA in the differential
diagnosis of thyroid nodules which were initially negative for
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BRAFV600E mutation on prior analysis, and in which circum-
stances this additional analysis can be effectively used.
Materials and Methods
This study has been approved by the institutional review board
(IRB) of Severance Hospital, Yonsei University (Seoul, Korea) and
informed consent has been waived by the IRB committee since the
study design was in a retrospective form. Informed consent for US-
FNA and BRAFV600E mutation analysis was obtained from all
patients included in this study, prior to all procedures.
Patients
This study was conducted at our institution (a referral center)
from June 2009 to April 2011. During this period, 2,365 patients
has undergone US-FNA and subsequent BRAFV600E mutation
analysis, of which 67 (2.8%) patients had undergone follow-up US-
FNA and BRAFV600E mutation analysis from the aspiration
specimen in 68 thyroid nodules. Among them, nodules showing
repeated non-diagnostic cytology on initial and follow-up US-FNA
(n= 9), benign (n = 2), or atypia (n = 8) on initial US-FNA cytology
without further follow-up surgical or imaging evaluation were
excluded. Thyroid nodules with negative BRAFV600E mutation
results on initial US-FNA which fulfilled the following criteria were
included: 1) surgery after US-FNA (n= 10), 2) benign cytology
results on both initial and follow-up US-FNA (n= 15), 3) no
changes on the follow-up US for at least 12 months after a benign
cytology result on initial or follow-up US-FNA (n= 22), or 4)
follow-up US-FNA cytology resulting in malignancy but without
surgery (n = 2) [17]. A total of 49 thyroid nodules in 49 patients
were finally included in this study (Fig 1).
At our institution, initial BRAFV600E mutation analysis was
performed based on requests from the referring clinicians based on
clinical features of the patient, the judegements of radiologists
performing US-FNA due to presence of suspicious US features of
the targeted nodule during US examinations. Follow-up
BRAFV600E mutation analysis was recommended in patients with
initial negative BRAFV600E mutation by the clinician, due to clinial
features arising suspicion for thyroid malignancy such as family
history of PTC (n= 1) or prior non-diagnostic (n = 13), atypia of
undetermined significance (n = 16) on initial US-FNA cytology
and benign cytology results in spite of the presence of suspicious
US features (n = 14), and unknown causes (n = 5).
Imaging Analysis
US examinations and subsequent US-FNA procedures were
performed using either 5– to 12– MHz linear probe (iU22, Philips
Medical Systemts, Bothell, WA) or 6– to 13– MHz linear probe
(EUB-7500, Hitachi Medical, Tokyo, Japan). Compoung imaging
was performed when using the iU22 machine.
During the study period, US and US-FNA were performed by 1
of 14 board-certified radiologists with 1–14 years of experience in
thyroid imaging. All radiologists had access to the medical record
of the patients such as clinical symptoms, past history, and prior
cytology and BRAFV600E mutation analysis results when perform-
ing US and US-FNA. US features of the thyroid nodules were
analyzed by the radiologist performing real-time US examinations
prospectively, according to the following categories; internal
Figure 1. Inclusion of the study population. US-FNA: ultrasonography-guided fine-needle aspiration biopsy, F/U: follow-up, BRAF: BRAFV600E
mutation analysis, Op: operation.
doi:10.1371/journal.pone.0058592.g001
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composition, echogenicity, margin, presence of calcifications,
shape and final assessment [19]. Malignant US features were
defined as markedly hypoechogenicity (echogenicity lower than
the adjacent strap muscle), non-circumscribed margins (micro-
lobulated or irregular margins), microcalcifications (tiny, punctate,
echogenic foci measuring less than 1 mm) [20] or mixed
calcifications (mixed macrocalcifications, including eggshell calci-
fications, and microcalcifications), and non-parallel ‘taller-than-
wide’ shape, based on a previously published criteria [19]. Final
assessments were given as ‘probably benign’, when none of the
suspicious US features mentioned above were present, and
‘suspicious malignant’, when 1 or more suspicious US features
were present in the thyroid nodule. Final reporting and
assessments of complicated cases was done after consulting senior
faculty members.
US-guided Fine-Needle Aspiration (US-FNA)
US-FNA was performed by the same radiologist who obtained
real-time US images of the thyroid nodule. US-FNAs were
performed on either thyroid nodules showing suspicious US
features or the largest nodule with probably benign assessment on
US, when none of the multiple thyroid nodules showed any
suspicious US features.
US-FNA was performed at least twice from each targeted
thyroid nodule using 23-gauge needles attatched to a 2 mL
disposable plastic syringe, without an aspirator. Aspirated material
was expelled on glass slides, which were smeared and immediately
placed into 95% alcohol, for Papanicolaou staining. The
remaining material in the syringe and needle hub was rinsed in
normal saline for cell block processing. Cytopathologists were not
present during US-FNA procedures, and additional staining of
cytology slides were performed, if needed, on a case-by-case basis
according to the request of the interpreting cytopathologist.
One of five cytopathologists specializing in thyroid pathology
interpreted the slides obtained from US-FNA. During the study
period of June 2009 to November 2009, cytology reports were
divided into the following categories: 1) non-diagnostic, indicating
specimen showing less than the required minimum of six
groupings of well-preserved thyroid follicular cells, each consisting
of at least 10 cells per group [21], 2) benign, 3) indeterminate
cytology, which includes follicular neoplasm and Hu¨rthle cell
neoplasm (22–23). 4) suspicious for malignancy, and 5) malignan-
cy. From December 2009 to the present, the Bethesda System for
reporting thyroid cytopathology was used in the classification of
cytology reports [21].
BRAFV600E Mutation Analysis
After US-FNA for cytology examinations, aspiration was
performed once more for BRAFV600E mutation analysis. Aspirated
material obtained was rinsed in 1 mL of normal saline, which was
sent for BRAFV600E mutation analysis.
Direct DNA sequencing was used in mutation analysis. Exon
15, which contains the BRAFV600E mutation, was amplified by
PCR with the foward primer AGGAAAGCATCTCACCTCATC
and the reverse primer GATCACACCTGCCTTAAATTGC.
The PCR parameters were as follows: 94uC for 5 minutes, 35
cycles at 94uC for 0.5 minutes, 60uC for 0.5 minutes, and 72uC for
10 minutes. The amplified products were purified with a
QIAGEN PCR purification kit and sequenced using the foward
primer described previously with Big Dye Terminator (ABI
Systems, Applied Biosystems, Foster City, CA), and an ABI
PRISM 3100 Avant Genetic Analyzer (Perkin-Elmer).
Data and Statistical Analysis
Histopathology results from surgery were considered the
standard reference. Cytology results were used as standard
reference for nodules which had not undergone surgery. Thyroid
nodules showing benign cytology results on either initial or follow-
up US-FNA cytology which did not show change on follow-up US
for at least 1 year were considered benign. Nodules diagnosed as
malignancy on US-FNA cytology which had not undergone
surgery were considered malignant.
Statistical comparison was performed using t-test for parametric
variables. X2-test or Fisher’s exact test was used in comparison of
non-parametric variables. Generalized estimated equation (GEE)
methods were used in comparing diagnostic performances. P
values of less than 0.05 were considered to have statistical
significance. Statistical analyses were performed using SAS
software (SAS system for Windows, version 9.1.3; SAS Institute,
Cary, NC).
Results
Of the 49 thyroid nodules included in this study, 12 (24.5%)
were malignancy and 37 (75.5%) were benign. Of the 49 patients,
6 (12.2%) were men and 43 (87.8%) were women. Mean age of the
patients were 50.4 years (range, 29 to 67 years), and mean size of
the thyroid nodules were 12.0 mm (range, 3 to 41 mm). Mean
interval between the initial and follow-up US-FNA and
BRAFV600E mutation analysis was 6.3 months (range, 3 to 21
months).
Clinical, radiological, and cytopathologic features of the patients
and thyroid nodules according to final pathology are summarized
in Table 1. Mean size of the thyroid nodules were significantly
smaller in malignancy (7.1862.93 mm) compared to benign
(13.4368.76 mm, P=0.023). No significant differences were seen
in mean age and gender between the benign and malignant
nodules.
SD: standard deviation
On US examinations, all 12 (100.0%) malignant nodules
showed 1 or more suspicious US features, while 20 (54.1%)
benign ones were assessed as suspicious malignant on US final
Table 1 Clinical, radiological, and cytopathologic
characteristics of the 49 patients and thyroid nodules
according to final pathology.
Benign Malignancy P
Number of nodules 37 (75.5%) 12 (24.5%) -
Mean age (years6SD) 50.7369.40 49.50610.39 0.431
Mean size of nodules
(mm6SD)
13.4368.76 7.1862.93 0.022
Patient gender 0.634
Men (%) 5 (13.5) 1 (8.3)
Women (%) 32 (86.5) 11 (91.7)
US Assessment 0.004
Probably benign (%) 17 (45.9) 0 (0.0)
Suspicious malignant (%) 20 (54.1) 12 (100.0)
2nd BRAFV600E mutation ,0.001
Negative (%) 37 (100.0) 5 (41.7)
Positive (%) 0 (0.0) 7 (58.3)
SD: standard deviation
doi:10.1371/journal.pone.0058592.t001
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assessment. Malignant nodules showed significantly higher rates of
suspicious US features compared to benign ones (P=0.004). Seven
(14.3%) of the 49 thyroid nodules was positive for the second
BRAFV600E mutation analysis, among which all were proven as
malignancy (Table 2). Initial US-FNA cytology of the 7 nodules
were non-diagnostic (n = 2), benign (n= 2), or atypia of undeter-
mined significance (n = 3), while follow-up US-FNA cytology were
benign (n = 1), indeterminate (n = 1), suspicious for malignancy
(n = 4), and malignancy (n= 1).
Of the 17 nodules with probably benign US final assessment,
initial US-FNA cytology results are as follows; 4 of non-diagnostic,
6 of benign, and 7 of atypia of undetermined significance. All 17
nodules were diagnosed as benign on follow-up cytology, showed
negative results on follow-up BRAFV600E mutation analysis, and
did not show significant changes on the serial follow-up US
examinations.
Final outcome of the 32 nodules with suspicious malignant US
assessment are summarized in Figure 2. Of the 32 nodules with
suspicious malignant US assessment, 12 (37.5%) were malignancy
and 20 (62.5%) were benign on final pathology. Of the 9 nodules
with initial non-diagnostic cytology, 3 nodules were diagnosed as
suspicious for malignancy (n = 1) or malignancy (n= 2) on follow-
up US-FNA. All 3 nodules were confirmed as PTC with surgery,
among which 2 showed positive results on follow-up BRAFV600E
mutation analysis (Fig 3). Of the 14 nodules with initial benign
cytology, 2 were diagnosed as indeterminate (n = 1) or suspicious
for malignancy (n= 1) on follow-up US-FNA, both with positive
results on follow-up BRAFV600E mutation analysis, and confirmed
as PTC on surgery. Eleven of the 14 nodules were diagnosed was
once again diagnosed as benign on follow-up US-FNA, showed
negative results on follow-up BRAFV600E mutation analysis. All 11
nodules were confirmed as benign. Of the 9 nodules with atypia on
initial cytology, 4 were diagnosed as benign on follow-up US-FNA,
of which 1 nodule was positive for BRAFV600E mutation on follow-
up analysis, and was confirmed as PTC on surgery (Fig 4).
Diagnostic performances of the follow-up US-FNA, follow-up
BRAFV600E mutation analysis alone, and follow-up US-FNA
combined with BRAFV600E mutation analysis are summarized in
Table 3. Sensitivity of US-FNA combined to BRAFV600E mutation
analysis was significantly higher than US-FNA alone (P=0.02),
while none of the other values showed significant differences.
Discussion
There is no doubt in that US-FNA is a safe, easy, and reliable
diagnostic method in the differential diagnosis of variable thyroid
nodules, but US-FNA has its limitations in that up to 10–30% of
the cytology derived from it can show inconclusive results, such as
insufficient material or indeterminate morphologic criteria of the
cells [15,21]. Molecular analysis of cytology specimen has
developed and contributed in providing additional information
in the differential diagnosis of thyroid nodules, with BRAF, RAS
mutations, and RET/PTC rearrangements most popularly used.
BRAFV600E mutation, in particular, is present in 29–70% of
papillary thyroid carcinoma [7–8,18], reaching up to 84% in
Korea, a BRAFV600E mutation-prevalent area [4,22]. Many
studies have looked into the factors related to BRAFV600E
mutation, mostly focusing on clinical [9,23–25], imaging or
cytology features [1,26–31]. However, to our knowledge there
are no studies in published literature that have investigated the
usefulness of follow-up BRAFV600E mutation analysis among
nodules negative for BRAFV600E mutation on initial analysis.
BRAFV600E mutation rate of the malignant nodules included in
this study was 58.3% (7 of 12 nodules), which is lower than the
reported 70–80% prevalence among Korean popluation [4,16].
This may be explained by the inclusion of thyroid nodules which
had initial negative BRAFV600E mutation results. Our study
included 49 thyroid nodule which had undergone two consecutive
rounds of US-FNA and BRAFV600E mutation analysis, all showing
negative BRAFV600E mutation on initial analysis. When putting
US assessements of the 49 thyroid nodules in consideration, all 17
nodules with probably benign features had negative results on
follow-up BRAFV600E mutation analysis and finally confirmed as
benign. Many recent reports show low malignancy rates among
thyroid nodules diagnosed as non-diagnostic, benign or atypia on
initial cytology showing no suspicious US features [21,32–33],
which may be further supported by the fact that this study
included nodules with negative results on initial BRAFV600E
mutation analysis. In contrast, 7 of the 32 nodules with suspicious
malignant US assessment were positive for BRAFV600E mutation
on follow-up analysis. Follow-up cytology results of the 7 nodules
were benign (n= 1), indeterminate (n = 1), suspicious for malig-
nancy (n= 4), and malignancy (n= 1). The Bethesda System for
Reporting Thyroid Cytopathology recommends repeating US-
FNA on thyroid nodules with non-diagnostic or atypia, and
diagnostic lobectomy on those with indeterminate or suspicious for
malignancy [21]. Similarly, the American Thyroid Association
management guidelines recommend follow-up US-FNA on
nodules diagnosed as non-diagnostic or atypia on cytology, and
either lobectomy or total thyroidectomy on those diagnosed as
indeterminate and suspicious for malignancy [15]. Follow-up US-
FNA is also recommended on thyroid nodules showing suspicious
US features which are diagnosed as benign on cytology [34–36].
When considering these recommendations, follow-up BRAFV600E
Table 2 Demographics of the 7 patients with positive BRAFV600E mutation on follow-up analysis.
No. Age Gender Size (mm) Inital US-FNA Follow-up US-FNA Final diagnosis
1 46 F 8 non-diagnostic suspicious for malignancy cPTC based on surgery
2 57 F 10 non-diagnostic malignancy Follow-up evaluation based on cytology
3 44 F 4 benign indeterminate cPTC based on surgery
4 45 F 7 benign suspicious for malignancy cPTC based on surgery
5 38 M 8 atypia benign cPTC based on surgery
6 54 F 5 atypia suspicious for malignancy cPTC based on surgery
7 58 F 6 atypia suspicious for malignancy FVPTC based on surgery
F: women, M: men
cPTC: conventional papillary thyroid carcinoma, FVPTC: follicular variant papillary thyroid carcinoma
doi:10.1371/journal.pone.0058592.t002
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mutation analysis confidently lead surgeons towards deciding upon
therapeutic surgery in 5 nodules with indeterminate and suspicious
for malignancy on follow-up cytology. Also, false-negative results
can occur in US-FNA [11,37]. and follow-up BRAFV600E
mutation contributed in detecting malignancy in 1 nodule with
false-negative cytology.
Diagnostic performances analysed in this study shows that when
combining the follow-up BRAFV600E mutation analysis results to
follow-up US-FNA alone, sensitivity was significantly improved,
83.3% to 91.7%, with specificity 100% in all combinations.
Among the 32 thyroid nodules with suspicious US features, 11
benign nodules had benign cytology on initial and follow-up US-
FNA, along with negative results on the two consecutive
BRAFV600E mutation analyses. When considering the high
specificity of BRAFV600E mutation analysis, two consecutive
negative results of BRAFV600E mutation analysis along with
negative cytology results may reassure clinicians in deciding upon
follow-up rather than diagnostic lobectomy, reducing unnecessary
diagnostic surgical procedures. But, among the 7 nodules showing
positive results on follow-up BRAFV600E mutation analysis, 6 were
had indeterminate, suspicious for malignancy or malignant
cytology results on follow-up US-FNA, presenting suspicious US
features. These results alone without the addition of follow-up
BRAFV600E mutation analysis may be an indication for therapeu-
tic surgery. But, US features in which surgeons rely upon in
deciding surgery involves a significant amount of subjectivity
produced by the operator, therefore, BRAFV600E mutation
analysis has its role in that it provides more objective information
regarding the targeted nodule. Although follow-up BRAFV600E
mutation analysis may not be useful in nodules diagnosed as
malignancy on follow-up US-FNA, it still has its strong points in
choosing upon therapeutic methods among nodules with indeter-
minate or suspicious for malignancy results on follow-up US-FNA.
Differences in BRAFV600E mutation results between US-FNA
cytology and pathology specimen obtained with surgery have been
reported in several studies [7,38]. As in a study on detection of
BRAFV600E mutation in indeterminate thyroid nodules [38], the
tumor cell contents of cytology specimen can limit the detection of
BRAFV600E mutation; even if the cancer tissues contain mutant
cells, if the cytology specimen does not include enough mutant
Figure 2. Final outcome of the 32 thyroid nodules with suspicious malignant US assessment. ND: non-diagnostic, BE: benign, IND:
indeterminate, SUSP: suspicious for malignancy, MAL: malignancy, cPTC: conventional papillary thyroid carcinoma, FVPTC: follicular variant of
papillary thyroid carcinoma
doi:10.1371/journal.pone.0058592.g002
Figure 3. 46-year-old woman with multiple thyroid nodules. US (a: transverse, b: longitudinal) revealed a 8-mm sized hypoechoic nodule
(arrows) with peripheral calcifications in the mid pole of left thyroid. US assessment was suspicious malignant. Initial US-FNA showed non-diagnostic
cytology and negative for BRAFV600E mutation. This nodule was diagnosed as suspicious for malignancy on follow-up US-FNA performed 11 months
later, and positive for BRAFV600E mutation. Surgery confirmed this lesion as PTC.
doi:10.1371/journal.pone.0058592.g003
Follow-up BRAFV600E Mutation Analysis
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cells BRAFV600E mutation analysis may show negative results.
Recently, highly sensitive analysis methods compared to direct
DNA sequencing such as pyrosequencing and dual priming
oligonucleotide (DPO)- based multiplex polymerase chain reaction
(PCR) have been introduced, showing abilities to detect less than
2–10% of mutant cells among the aspirated specimen [22,39], but
still, it is clear that obtaining enough mutant cells during US-FNA
procedures is important in getting accurate results. The gap
between the two consecutive BRAFV600E mutation analysis of our
study may be explained by the differences between the initial and
follow-up cytology results of the 7 nodules; while initial cytology
results were non-diagnostic, benign or atypia, follow-up cytology
consists of suspicious for malignancy or malignancy in 5 of the 7
nodules. In contrast to the previously mentioned studies, although
obtaining enough cells during aspiration is critical, BRAFV600E
mutation analysis has shown high sensitivity regardless of the
analysis method, even in cytology specimen somewhat insufficient
for accurate diagnosis [22,40–41]. Even though BRAFV600E
mutation has its limitations, it has improved the selection of
thyroid nodules for surgical treatment in our study; BRAFV600E
mutation was detected in the 2 nodules with benign and
indeterminate follow-up cytology results in our study, further
confirming its efficacy in the diagnosis of PTC.
There are several limitations to our study. First, a limited
number of patients and thyroid nodules with initial and follow-up
BRAFV600E mutation were included in this retrospective study. As
the indication or the cost-effectiveness of follow-up BRAFV600E
mutation analysis has not yet been proven, few patients had
undergone follow-up analysis, and selection bias may have existed.
Further studies in a large series is anticipated. Second, 14
radiologists with various experiences in thyroid imaging were
involved in US assessment and US-FNA procedures. Observer
variability among radiologists may have affected US assessments
and cytology results of thyroid nodules. Similarly, 5 cytopathol-
ogists were involved in cytology slide interpretation, and interob-
Figure 4. 38-year-old man with multiple thyroid nodules. A 8-
mm sized hypoechoic nodule (empty arrows) with suspicious calcifica-
tions (arrows), and spiculated margins was seen in right lower isthmus
on US. US assessment was suspicious malignant. Initial US-FNA was
diagnosed as atypia of undetermined significance, and negative for
BRAFV600E mutation. Follow-up US-FNA and BRAFV600E mutation analysis
was performed 6 months later, and follow-up cytology was diagnosed
as benign, but positive results on BRAFV600E mutation analysis. Surgery
was performed, and this nodule was confirmed as PTC.
doi:10.1371/journal.pone.0058592.g004
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server variability among cytopathologists may have affected the
US-FNA cytology results. Last, 2 of the 13 malignant nodules were
diagnosed based on cytology only, and the 17 benign nodules were
considered benign based on cytology results and US follow-up
examinations. False-positive and false-negative results can occur in
US-FNA, reported false-positive rates are 0.2–5.7% [42–43], false-
negative rates 1.9–5.8% [34,44], which may have had effect on
our results.
In conclusion, follow-up BRAFV600E mutation analysis may be
helpful in the diagnosis of selected thyroid nodules negative for
BRAFV600E mutation on initial analysis, which are assessed as
suspicious malignant on US, diagnosed as non-diagnostic, benign
or atypia on follow-up US-FNA.
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